containment of the global pandemic. At present, vaccines seem to be the most important and effective longterm intervention we have at hand to contain a potentially deadly virus that will most probably continue to circulate in the human population for the foreseeable future.⁴

I declare no competing interests.

Carsten Krüger carsten.krueger@uni-wh.de

Department of Medicine, Division of Paediatrics, Witten/Herdecke University, 58448 Witten, Germany; Department of Applied Health Sciences, University of Applied Sciences, Bochum, Germany

- Priesemann V, Brinkmann MM, Ciesek S, et al. Calling for pan-European commitment for rapid and sustained reduction in SARS-CoV-2 infections. Lancet 2021; 397: 92–93.
- 2 Michie S, West R. Behavioural, environmental, social, and systems interventions against covid-19. BMJ 2020; 370: m2982.
- 3 Schippers MC. For the greater good? The devastating ripple effects of the Covid-19 crisis. Front Psychol 2020; **11:** 577740.
- 4 Sewell HF, Agius RM, Kendrick D, Stewart M. Covid-19 vaccines: delivering protective immunity. BMJ 2020; 371: m4838.

Authors' reply

We thank Carsten Krüger for the opportunity to further elaborate on the important aspects raised in his Correspondence.

First, we are definitely concerned about the impact of lockdowns and continued severe restrictions on the various aspects of human life mentioned. That is precisely why we are committed to the goal of pursuing low case numbers.¹ These are necessary to ease restrictions moderately without jeopardising millions of lives and livelihoods.2 The argument is straightforward: uncontained spread would lead to high numbers of deaths and many cases of so-called long COVID, not to mention overburdened health-care systems with collateral impact for everyone. The central idea supporting strong lockdowns and thus rapid case reduction is that strong and effective lockdowns minimise the duration of negative social impacts. In a follow-up statement with coauthors from the humanities and social sciences, we go into more depth on these important socioeconomic aspects.³

Second, we welcome all efforts towards international cooperation and coordination on this matter. Indeed, with this initiative, we hope to promote more cooperation rather than narrow national perspectives. The common legal and institutional framework of the EU allows for a comprehensive joint strategy that can be implemented immediately. A global strategy follows more easily from this important first step. The statement further points to challenges specific to Europe, such as open borders and highly interconnected societies and economies. However, considering that settings of countries all around the world might display larger differences, all these arguments can be immediately generalised to a more global perspective.

Vaccinations play a central role in pandemic response. Nonetheless, it will be a while until vaccination takes full effect, and hence we need a sustainable strategy for the coming months and years.3 The vaccination effect will not be sustainable until all people worldwide have had access to vaccination, further underscoring the importance of international cooperation. Further factors that diminish or slow vaccination progress include obstructions in vaccine production and delivery, the possibility of transmission despite vaccination, and the emergence of escape variants that bypass immunity.3 The latter might even require further vaccine development and the restarting of vaccination programmes. In light of all this, it is necessary that restrictions continue to be maintained for the time being. Hence, low case numbers in the coming months or possibly years, at least below ten per million people per day, have clear benefits for allfor public health, society, and the economy.3

SCi reports grants and personal fees from Roche, and personal fees from Euroimmun, unrelated to this Correspondence. NH reports grants from GSK Biologicals, Pfizer, Merck, and Johnson & Johnson, unrelated to this Correspondence. All other authors declare no competing interests.

*Viola Priesemann,

Melanie M Brinkmann, Sandra Ciesek, Sarah Cuschieri, Thomas Czypionka, Giulia Giordano, Claudia Hanson, Niel Hens, Emil Iftekhar, Peter Klimek, Mirjam Kretzschmar, Andreas Peichl, Matjaž Perc, Francesco Sannino, Eva Schernhammer, Alexander Schmidt, Anthony Staines, Ewa Szczurek viola.priesemann@ds.mpg.de

Max Planck Institute for Dynamics and Self- Organization, 37077 Göttingen, Germany (VP, EI, ASc); Technische Universität Braunschweig, Helmholtz Zentrum für Infektionsforschung, Braunschweig, Germany (MMB); University Hospital, Goethe-University Frankfurt, Frankfurt, Germany (SCi); Faculty of Medicine & Surgery, University of Malta, Msida, Malta (SCu); Institute for Advanced Studies, Vienna, Austria (TC); London School of Economics and Political Science, London, UK (TC); University of Trento, Trento, Italy (GG); London School of Hygiene & Tropical Medicine, London, UK (CH); Karolinska Institute, Stockholm, Sweden (CH): I-BioStat, Data Science Institute, Hasselt University, Hasselt, Belgium (NH); Centre for Health Economic Research and Modelling Infectious Diseases, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium (NH); Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria (ESc), University Medical Center Utrecht, Utrecht, Netherlands (EI, MK); Medical University of Vienna, Vienna, Austria (PK); Complexity Science Hub Vienna, Vienna, Austria (PK); ifo Institute, Leibniz Institute for Economic Research, University of Munich, Munich, Germany (AP): University of Maribor, Maribor, Slovenia (MP); Federico II University of Napoli, Napoli, Italy (FS); Centre of Excellence for Particle Physics and Cosmology and Danish Institute for Advanced Study, University of Southern Denmark, Aarhus, Denmark (FS); Campus Institute for Dynamics of Biological Networks, Göttingen, Germany (ASc); School of Nursing, Psychotherapy and Community Health, Dublin City University, Dublin, Ireland (ASt); Faculty of Mathematics, Informatics and Mechanics, University of Warsaw, Warsaw, Poland (ESz)

- 1 Priesemann V, Brinkmann MM, Ciesek S, et al. Calling for pan-European commitment for rapid and sustained reduction in SARS-CoV-2 infections. *Lancet* 2021; **397:** 92–93.
- Contreras S, Dehning J, Loidolt M, et al. The challenges of containing SARS-CoV-2 via test-trace-and-isolate. *Nat Commun* 2021; 12: 378.
- 3 Priesemann V, Balling R, Brinkmann MM, et al. An action plan for pan-European defence against new SARS-CoV-2 variants. *Lancet* 2021; **397**: 469–70.

